The apples and oranges of cost-effectiveness

Cleveland Clinic Journal of Medicine

Volumn 79, Issue 6, 2012, Pages 377-379

  Prasad, Vinay ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; EXEMESTANE;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; METHODOLOGY; NOTE; PERCUTANEOUS VERTEBROPLASTY;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; VERTEBROPLASTY;

EID: 84862997694     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79a.11087     Document Type: Note

References (13)

1. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 2009; 361:569-579.
2. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009; 361:557-568.
3. Masala S, Ciarrapico AM, Konda D, Vinicola V, Mammucari M, Simonetti G. Cost-effectiveness of percutaneous vertebroplasty in osteoporotic vertebral fractures. Eur Spine J 2008; 17:1242-1250.
4. Goss PE, Ingle JN, Alés-Martínez JE, et al; NCIC CTG MAP3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381-2391.
5. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165:725-730.
6. van Staa TP, Leufkens HG, Zhang B, Smeeth L. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med 2009; 6:e1000194.
7. Prasad V, Cifu A. A medical burden of proof: towards a new ethic. BioSocieties 2012; 7:72-87.
8. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010; 170:1024-1031.
9. National Heart, Lung, and Blood Institute National Institutes of Health. AIM-HIGH: Blinded treatment Accessed January 31 phase of study stopped. http://www.aimhigh-heart.com , 2012.
10. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367.
11. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461.
12. Mesotten D, Van den Berghe G. Clinical potential of insulin therapy in critically ill patients. Drugs 2003; 63:625-636.
13. NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297.